Business Wire

FACE

24.1.2024 07:01:27 CET | Business Wire | Press release

Share
New Survey Sheds Light on European Acceptance of So-Called “Trophy” Hunting

A survey conducted by YouGov1 and commissioned by the European Federation for Hunting and Conservation (FACE) and partner organisations, has unveiled a significant acceptance of international hunting, often mislabelled as “trophy” hunting.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240123042824/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Infographic on Public Opinion on So-Called "Trophy" Hunting in Europe (Photo: FACE – the European Federation for Hunting and Conservation)

The independent sample survey by YouGov2 of over 7000 Europeans from five countries, shows that a majority of EU citizens accept hunting. Only 23% disagree with keeping animal parts, a practice often referred to as “trophy” hunting, whilst 77% either approve or are neutral.

This starkly contrasts the claim that 85% of Europeans oppose “trophy” hunting made by the Humane Society International3. Their misdirection has resulted in several national parliaments initiating efforts to ban “trophy” imports.

The survey, conducted in November 2023, aimed to ascertain unbiased public opinion on the social acceptance of domestic and international hunting. A focus was on the retention of animal parts (e.g. horns, antlers, etc.) as well as the acceptance of legal hunting that benefits conservation.

These findings challenge a narrow perception of hunting as solely targeting "trophies” of charismatic species, as often propagated by animal rights organisations.

Therefore, bans or restrictions on the movement of legally obtained “trophies” are not supported by society, and negatively impact local communities, economies, and biodiversity.

The International Union for Conservation of Nature (IUCN) briefing paper,4 states that “trophy hunting…can and does generate critically needed incentives and revenue for government, private and community landowners to maintain and restore wildlife as a land use and to carry out conservation actions”

For the complete report on the public attitude toward “trophy” hunting, see here.

About Us: FACE – the European Federation for Hunting and Conservation is the voice of 7 million European Hunters and represents 37 national members.

_________________________________
1 All data are provided by YouGov PLC. 7.188 respondents participated in the survey, which took place between the 30.10. and 21.11.2023 in Germany, Italy, Spain, Denmark and Poland. The results were weighted and are representative for the population (age 18+) in the respective country.
2 The survey was conducted by independent polling company YouGov at the request of sustainable use organisations: CIC – International Council for Game and Wildlife Conservation, Safari Club International, Dallas Safari Club, Wild Sheep Foundation, Conservation Force, and the International Professional Hunters Association.
3 https://www.hsi.org/wp-content/uploads/2021/05/eu-trophy-hunting-poll.pdf
4 https://portals.iucn.org/library/efiles/documents/Rep-2012-007.pdf

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240123042824/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye